Advancing a new generation of treatments for
central nervous system disorders
Latest News
26 Jan 2012
NeurOp Awarded Deal of the Year for Ischemia Program Funding
Read More
14 Dec 2011
NeurOp Announces Extension to Drug Discovery Collaboration with Bristol-Myers Sq ...
Read More
18 Oct 2011
NeurOp Selected for NIH Commercialization Assistance Program to Support Drug Dev ...
Read More
NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders,
including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of
N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling.
Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented
opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.
Learn more about our science.